524348 Stock Overview
Aarti Drugs Limited, through its subsidiaries, engages in the manufacturing and marketing of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 4/6 |
Past Performance | 3/6 |
Financial Health | 5/6 |
Dividends | 2/6 |
Aarti Drugs Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₹441.10 |
52 Week High | ₹645.00 |
52 Week Low | ₹332.15 |
Beta | 0.90 |
1 Month Change | -14.12% |
3 Month Change | -10.65% |
1 Year Change | 30.81% |
3 Year Change | -36.51% |
5 Year Change | 185.55% |
Change since IPO | 14,603.33% |
Recent News & Updates
Recent updates
Shareholder Returns
524348 | IN Pharmaceuticals | IN Market | |
---|---|---|---|
7D | 0.6% | 2.7% | 2.5% |
1Y | 30.8% | 63.9% | 47.3% |
Return vs Industry: 524348 underperformed the Indian Pharmaceuticals industry which returned 65% over the past year.
Return vs Market: 524348 underperformed the Indian Market which returned 48.6% over the past year.
Price Volatility
524348 volatility | |
---|---|
524348 Average Weekly Movement | 3.8% |
Pharmaceuticals Industry Average Movement | 5.9% |
Market Average Movement | 6.6% |
10% most volatile stocks in IN Market | 10.1% |
10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: 524348 has not had significant price volatility in the past 3 months.
Volatility Over Time: 524348's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1984 | 1,003 | Prakash Patil | https://www.aartidrugs.co.in |
Aarti Drugs Limited, through its subsidiaries, engages in the manufacturing and marketing of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company provides APls in various therapeutic areas, including anti-inflammatory, cardioprotectants, antidiarrhoeals, antifungals, antiarthritis/osteoporosis, antibiotics, antidiabetics, Alzheimer’s treatment, sedatives, vitamins, and alcoholism treatment; and pharmaceutical intermediate products comprising tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, nimesulide, and raloxifene. It also offers specialty chemical products, such as benzene sulphonyl chloride, benzene sulphonic acid, benzene sulphonic acid methyl ester, sodium benzene sulfinate, para toluene sulphonyl chloride, para toluene sulphonic acid methyl ester, N,N',N'-tris-(4-toluene sulfonyl)-diethylenetriamine, sodium para toluene sulfinate, para toluene sulphonyl hydrazide, di-phenyl sulphone, formamide, ammonium sulfate, and calcium fluoride, as well as benzene sulphonic acid sodium salt, benzyl nicotinate, methyl nicotinate, ethyl para toluene sulphonate, N-methyl methane sulfonamide, benzene sulphonamide, 2-phenoxy methane sulphanilide, para toluene sulfonamides, para chloro benzene sulphonamide, para chloro benzene sulphonyl chloride, ortho para toluene sulfonamides, ortho para toluene sulfonamides acid methyl ester, and N-methyl methane sulfonamides.
Aarti Drugs Limited Fundamentals Summary
524348 fundamental statistics | |
---|---|
Market cap | ₹40.55b |
Earnings (TTM) | ₹1.80b |
Revenue (TTM) | ₹26.51b |
22.5x
P/E Ratio1.5x
P/S RatioIs 524348 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
524348 income statement (TTM) | |
---|---|
Revenue | ₹26.51b |
Cost of Revenue | ₹18.18b |
Gross Profit | ₹8.33b |
Other Expenses | ₹6.53b |
Earnings | ₹1.80b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 19.60 |
Gross Margin | 31.43% |
Net Profit Margin | 6.80% |
Debt/Equity Ratio | 48.7% |
How did 524348 perform over the long term?
See historical performance and comparison